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Hematopoietic stem cell transplantation (HSCT) is a curative therapy for severe aplastic anemia (SAA);
however, the optimal conditioning regimen for HSCT with an unrelated donor has not yet been deﬁned. A
previous study using a ﬂudarabine (FLU), cyclophosphamide (Cy), and antithymocyte globulin
(ATG) conditioning regimen (study A: 50 mg/kg Cy once daily i.v. on days 9, 8, 7, and 6; 30 mg/m2 FLU
once daily i.v. on days 5, 4, 3, and 2; and 2.5 mg/kg of ATG once daily i.v. on days 3, 2, and 1)
demonstrated successful engraftment (100%) but had a high treatment-related mortality rate (32.1%).
Therefore, given that Cy is more toxic than FLU, we performed a new phase II prospective study with a
reduced-toxicity regimen (study B: 60 mg/kg Cy once daily i.v. on days 8 and 7; 40 mg/m2 FLU once daily
i.v. on days 6, 5, 4, 3, and 2; and 2.5 mg/kg ATG once daily i.v. on 3 days). Fifty-seven patients were
enrolled in studies A (n ¼ 28) and B (n ¼ 29), and donor type hematologic recovery was achieved in all
patients in both studies. The overall survival (OS) and event-free survival (EFS) rates of patients in study B was
markedly improved compared with those in study A (OS: 96.7% versus 67.9%, respectively, P ¼ .004; EFS:
93.3% versus 64.3%, respectively, P ¼ .008). These data show that a reduced-toxicity conditioning regimen
with FLU, Cy, and ATG may be an optimal regimen for SAA patients receiving unrelated donor HSCT.
 2016 American Society for Blood and Marrow Transplantation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).dgments on page 1459.
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Bone marrow (BM) transplantation with a matched sib-
ling donor is a curative therapy for severe aplastic anemia
(SAA). Studies have demonstrated that the optimalThis is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient Characteristics and Transplantation Data
Study A
(n ¼ 28)
Study B
(n ¼ 29)
P
Median age, yr (range) 13.5 (1.2-29.8) 12.9 (6.4-19.8) .52
Sex .672
Male 17 (60.7) 16 (55.2)
Female 11 (39.3) 13 (44.8)
Interval from diagnosis
to transplantation
.889
<1 yr 13 (46.4) 14 (48.3)
1 yr 15 (53.6) 15 (51.7)
History of previous IST .02
Yes 14 (50.0) 6 (20.7)
No 14 (50.0) 23 (79.3)
Stem cell source .004
BM 15 (53.6) 5 (17.2)
PB 13 (46.4) 24 (82.8)
Median infused cell
dose, (range)
TNC, 108/kg 6.8 (1.3-26.5) 11.6 (1.3-218.4) .137
CD34, 106/kg 5.2 (1.2-23.9) 6.4 (1.3-27.5) .601
HLA disparity, 8/8 (HLA-A,
-B, -C, -DR)
.215
0/8 19 (67.9) 15 (51.7)
1/8 9 (32.1) 14 (48.3)
GVHD prophylaxis .001
CsA based 20 (71.4) 8 (27.6)
FK based 8 (28.6) 21 (72.4)
TNC indicates total nucleated cell; CsA, cyclosporine.
Values are number of cases with percents in parentheses, unless otherwise
indicated.
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nation of cyclophosphamide (Cy) and antithymocyte glob-
ulin (ATG) followed by graft-versus-host disease (GVHD)
prophylaxis with methotrexate and cyclosporine [1,2].
However, many patients have no appropriate sibling donor
and must choose another treatment, such as immunosup-
pressive therapy (IST) and/or hematopoietic stem cell
transplantation (HSCT) with an alternative donor [3].
Furthermore, because the Cy and ATG regimen is not sufﬁ-
cient for HSCT with an alternative donor [4], other condi-
tioning regimens, such as the inclusion of total body
irradiation (TBI) [5,6] or ﬂudarabine (FLU)-based therapies
[7], have been used to improve outcomes. In addition, studies
have shown promising survival rates using new HLA typing
techniques [5] and GHVD prophylaxis [8,9].
We previously reported the results of a phase II, pro-
spective, multicenter clinical trial conducted with a FLU, Cy,
and ATG conditioning regimen (study A) [10]. This regimen
resulted in good engraftment after unrelated donor (UD)
HSCT for patients with SAA; however, the event-free survival
(EFS) rate was 67.9%, and all adverse events (except for 1
patient with secondary graft failure) were treatment-related
mortalities (TRMs). Consequently, we conducted a newly
designed multicenter clinical trial with a reduced-toxicity
conditioning regimen (study B) to help improve survival.
Here, the aim of the present study was to compare the safety
and efﬁcacy of study A and study B and to ﬁnd the optimal
conditioning regimen for SAA patients receiving UD HSCT.METHODS
Patient and Donor Selection
Fifty-seven patients (28 in study A and 29 in study B) with SAA received
UD HSCT at multiple centers across Korea. Patients who did not have a prior
history of HSCT, who had an Eastern Cooperative Oncology Group perfor-
mance status of 0 to 2, who were free of signiﬁcant functional problems in
major organs (ejection fraction > 45%, total bilirubin < 2  upper limit of
normal, alanine transaminase < 3  upper limit of normal, and
creatinine < 2  upper limit of normal), and who did not have any active
viral or fungal infection were included in both studies. All patients with
congenital aplastic anemia, including Fanconi anemia, were excluded. The
clinical characteristics of patients in both studies are summarized in Table 1.
The median age, sex, and period between diagnosis and HSCT were not
signiﬁcantly different between participants in study B and study A. How-
ever, study B patients were less likely to have a history of IST (P ¼ .020).
For donor selection HLA-A, -B, -C, and -DRB1 matching was conﬁrmed
by a high-resolution molecular method for all patients and donors. All pa-
tients received the designated conditioning regimen after providing
informed consent. Both studies were approved by the institutional review
board of each center and registered at www.clinicaltrials.gov (NCT00737685
and NCT00882323, respectively).Conditioning Regimen
The study A conditioning regimen was composed of Cy (50 mg/kg once
daily i.v. on days 9, 8, 7, and 6), FLU (30 mg/m2 once daily i.v. on
days 5, 4, 3, and 2), and ATG (Thymoglobulin; SangStat, Lyon, France
and Genzyme, Cambridge, MA; 2.5 mg/kg once daily i.v. on days 3, 2,
and1). The regimen used in study B was composed of a reduced dose of Cy
(60 mg/kg once daily i.v. on days 8 and 7), an increased dose of FLU
(40 mg/m2 once daily i.v. on days 6, 5, 4, 3, and 2), and the same
dose of ATG (2.5 mg/kg once daily i.v. on 3 days). To prevent hemorrhagic
cystitis, patients received mesna and adequate hydration.GVHD Prophylaxis and Supportive Care
Each institution used their own GVHD prophylaxis protocol. In study A a
cyclosporine-based protocol was used more often, whereas a tacrolimus
(FK)-based protocol was usedmore often in study B (P¼ .001). Each protocol
included methotrexate regardless of post-transplant, low-dose ATG
(1.25mg/kg once daily i.v. on days 7, 9, and 11) [11,12]. Epstein-Barr viral load
monitoring was regularly conducted in study B, although it could not be
done uniformly according to the institutions in study A. Supportive care was
performed according to the protocols of each institution.Assessment of Engraftment and Toxicity
Neutrophil engraftment was deﬁned as the ﬁrst day of 3 consecutive
days with an absolute neutrophil count (ANC)> .5 109/L. Platelet recovery
was deﬁned as the ﬁrst day with a platelet count > 20  109/L without
platelet transfusions. Hematopoietic chimerismwas evaluated using a serial
analysis of short tandem repeats of BM aspirates at 1, 3, 6, and 12 months
post-HSCT. Secondary graft failure was deﬁned as engraftment followed by
severe neutropenia (ANC < .5  109/L) or the absence of donor cells in the
BM or peripheral blood (PB), as demonstrated by a chimerism assay, without
subsequent improvement occurring either spontaneously or after treatment
with a growth factor. BM or PB stem cell reinfusion, which was administered
any time after day 0 if indicated by inadequate hematopoietic function, was
taken as a deﬁnitive indication of graft failure regardless of ANC values and
BM cellularity. In study B the regimen-related toxicity up to 42 days after
transplantation was graded according to the National Cancer Institute
CommonTerminology Criteria for Adverse Events, version 4.0. In study A the
regimen-related toxicity, which was previously graded according to the
National Cancer Institute Common Toxicity Criteria for BM transplant re-
cipients (version 2.0), was converted to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, version 4.0.
Statistical Analyses
Categorical variables and continuous variables were compared using a
chi-square test and Student’s t-test, respectively. Acute and chronic GVHD
were computed using the cumulative incidence (CI) function. For both, the
competing risks were graft failure and TRM. Overall survival (OS) and EFS
were analyzed using the Kaplan-Meier method. The difference in CI curves
was examined using a Gray’s test, whereas the difference in survival rates
was determined using the log-rank test. A Cox proportional hazard regres-
sion model was used for the multivariate analysis of prognostic factors
affecting survival. P < .05 was considered to be statistically signiﬁcant.
Statistical analyses were performed using R version 3.2.2 (www.r-projec-
t.org) and SPSS 20.0 (IBM-SPSS, Armonk, NY).
RESULTS
Transplantation and Engraftment Data
HLA disparity as well as the median infused dose of
nucleated cells and the median infused dose of CD34þ cells
were not signiﬁcantly different between study A and study B.
However, PB was used more often as a stem cell source in
study B than in study A (Table 1). Themedian number of days
Table 2
Infection and Organ Toxicity Rates for Patients in Study A and Study B
Study A
(n ¼ 28)
Study B
(n ¼ 29)
P
Veno-occlusive disease 0 (.0) 1 (3.4) 1.000
CMV infection
Antigenemia 21 (75.0) 19 (65.5) .434
Disease 2 (7.1) 1 (3.4) .611
PTLD 5 (17.9) 2 (6.9) .253
Organ toxicities, grades 3-4
Bladder 10 (35.7) 1 (3.4) .003
Cardiac 1 (3.6) 0 (.0) .491
CNS 3 (10.7) 0 (.0) .112
GI 7 (25.0) 6 (20.7) .698
Hepatic 5 (17.9) 9 (31.0) .358
Febrile neutropenia 13 (46.4) 23 (79.3) .010
Pulmonary 4 (14.3) 1 (3.4) .194
Renal 3 (10.7) 0 (.0) .112
Skin 1 (3.6) 3 (10.3) .611
CMV indicates cytomegalovirus; CNS, central nervous system; GI, gastro-
intestinal.
Values are number of cases with percents in parentheses.
Figure 1. EFS and OS curves according to the study group. (A) EFS by study
group. (B) OS by study group. Study B (the reduced-toxicity regimen) showed
markedly improved EFS and OS when compared with study A.
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(range, 10 to 32) and 12 days (range, 10 to 23), respectively.
Platelet recovery without transfusion required a median of
22 days (range, 11 to 179; except for 1 patient with TRM) in
study A and of 16 days (range, 8 to 127 days; except in 1
patient with TRM) in study B. All patients achieved donor-
type chimerism > 90% on day 28 post-HSCT; nevertheless,
secondary graft failure occurred in 2 patients (study A: 1
patient, 37 months after HSCT; study B: 1 patient, 3 months
after HSCT). One underwent a successful second HSCT and
the other achieved donor-type hematologic recovery again
after steroid pulse therapy.
Treatment-Related Mortality
In study A 9 patients died of a TRM, resulting in a CI of
32.1%. TRM was related to post-transplantation lymphopro-
liferative disease (PTLD; n ¼ 3), thrombotic microangiopathy
(n ¼ 2), chronic GVHDeassociated complications (n ¼ 2),
pneumonia (n ¼ 1), and myocardial infarction (n ¼ 1).
However, only 1 patient died of TRM (caused by pneumonia)
in study B (CI, 3.5%).
Graft-versus-Host Disease
Between study A and B therewere no differences in the CI
of grades II to IV acute GVHD (46.4% versus 41.3%, respec-
tively, P¼ .771) and grades III to IV acute GVHD (14.8% versus
3.5%, respectively, P¼ .294). Although the CI of chronic GVHD
also did not differ signiﬁcantly between the 2 groups (35.7%
versus 37.9%, respectively, P ¼ .910), extensive chronic GVHD
occurred in 4 patients in study A and 5 patients in study B
(14.3% versus 17.2%, respectively, P ¼ .754).
Toxicity and Infection
In study A grades 3 to 4 regimen-related toxicity up to
42 days after HSCT occurred in 18 patients (64.3%). In study B
24 patients (82.8%) showed grades 3 to 4 toxicity, but most of
them had febrile neutropenia (n ¼ 23, 79%) that was treated
without mortality. Bladder toxicity, particularly hemorrhagic
cystitis, was markedly decreased in patients in study B
compared with those in study A (3.4% versus 35.7%, respec-
tively, P ¼ .003).
Cytomegalovirus infection occurred in 21 patients in
study A and 19 patients in study B (CI: 75.0% versus 65.5%,
respectively, P¼ .434), and cytomegalovirus disease occurred
in 2 patients in study A and 1 patient in study B (CI: 7.1%
versus 3.4%, respectively, P ¼ .611). PTLD developed in 5 pa-
tients in study A and 2 patients in study B (CI: 17.9% versus
6.9%, respectively, P¼ .253). Three of the 5 patients in study A
with PTLD died due to PTLD, whereas in study B 1 patient
improved after including rituximab and 1 improved after
stopping FK. More information regarding infection and
toxicity rates is shown in Table 2.
Survival Data and Prognostic Factors
To determine the prognostic factors for survival, the total
samples in studies A and B were analyzed together. In the
univariate analysis, the EFS rate of study B was 93.1%, which
is markedly higher when compared with that of study A
(64.3%, P ¼ .008). Moreover, the OS rate in study B was also
higher than that of study A (96.6% versus 67.9%, respectively,
P¼ .004; Figure 1). In addition, a history of IST affected the OS
rate signiﬁcantly (P ¼ .048).
However, in the multivariate analysis, which included all
factors with a P < .250 in the univariate analysis, only the
study group was identiﬁed as a signiﬁcant prognostic factorfor EFS (exp [B] .150, P ¼ .027). In the present study, other
factors such as the period between diagnosis and HSCT, stem
cell source, HLA disparity, GVHD prophylaxis, and age at
HSCT were not signiﬁcantly associated with OS or EFS
(Table 3).
Table 3
Univariate and Multivariate Analyses of EFS and OS among the Total Sample
EFS OS
No. (%) P* Py Exp[B] (95% CI) No. (%) P* Py Exp[B] (95% CI)
History of previous IST .149 .776 .776 (.359-3.953) .048 .370 1.845 (.483-7.043)
Yes (n ¼ 20) 14 (70.0) 14 (70.0)
No (n ¼ 37) 31 (83.8) 33 (89.2)
Interval from diagnosis
to transplantation
.102 .13 3.126 (.715-13.659) .238 .496 1.727 (.483-7.043)
<1 yr (n ¼ 27) 24 (88.9) 24 (88.9)
1 yr (n ¼ 30) 21 (70.0) 23 (76.7)
Stem cell source .201 .614 1.407 (.373-5.310) .065 .85 .865 (.192-3.896)
BM (n ¼ 20) 14 (70.0) 14 (70.0)
PB (n ¼ 37) 31 (83.8) 33 (89.2)
HLA disparity, 8/8 (HLA-A,
-B, -C, -DR)
.660 .540
0/8 (n ¼ 34) 26 (76.5) 27 (79.4)
1/8 (n ¼ 23) 19 (82.6) 20 (87.0)
GVHD prophylaxis .472 .415
CsA based (n ¼ 28) 21 (75.0) 22 (78.6)
FK based (n ¼ 29) 24 (82.8) 25 (86.2)
Age at HSCT .5 .482
13 yr (n ¼ 29) 24 (82.8) 25 (86.2)
>13 yr (n ¼ 28) 21 (75.0) 22 (78.6)
Study group .008 .027 .15 (.028-.808) .004 .057 .116 (.013-1.063)
Study A (n ¼ 28) 18 (64.3) 19 (67.9)
Study B (n ¼ 29) 27 (93.1) 28 (96.6)
CI indicates conﬁdence interval.
* Univariate analysis.
y Multivariate analysis.
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This study aimed to investigate the safety and efﬁcacy of a
reduced-toxicity conditioning regimen for SAA patients
receiving UD HSCT. Although the results of study A demon-
strated good engraftment, the TRM rate was relatively high
[10]. Therefore, the dosage of the medications used in the
conditioning regimen was changed and re-evaluated in a
second prospective clinical trial. The second regimen (study
B) demonstrated a deﬁnitive beneﬁt for EFS and OS without
decreasing the engraftment potency.
Recently, FLU-based conditioning regimens for SAA pa-
tients receiving UD HSCT have shown promising results
[7,13-17], and a 95% failure-free survival rate has been re-
ported with a FLU, Cy, and alemtuzumab conditioning
regimen [16]. However, the exact dose of each conditioning
medication has not yet been fully deﬁned. For example, in a
retrospective study from the European Group for Blood and
Marrow Transplantation [7], graft failure/rejection was re-
ported in 17% of the total sample, which may be explained by
a lower than conventional dose of Cy (1200 mg/m2). On the
other hand, Tolar et al. [18] proposed that a Cy dose com-
bined with FLU should range between 50 and 100 mg/kg to
prevent excessive organ toxicity. Fortunately, recent studies
showed that Cy 50 mg/kg is the most desirable dose in
combination with TBI 2 Gy, FlU 120 mg/m2, and ATG for UD
HSCT for SAA [19,20].
In study B we reduced the dose of Cy (120 mg/kg divided
into 2 doses) and increased the dose of FLU (200 mg/m2
divided into 5 doses). Reducing the dose of Cy resulted in a
dramatic effect on EFS. Moreover, hemorrhagic cystitis
decreased, representing an overall reduction in conditioning
regimen toxicity. On the other hand, the dose of FLU in study B
was relatively higher than in other studies [7,16]. Because our
conditioning regimenwas a noneTBI-containing regimen, we
selected the relatively higher cumulative FLU dose in study B.
However, it did not cause TRM or severe organ toxicity and
showed engraftment outcomes similar to study A. We alsohave previously reported that high cumulative FLU doses (200
to 240 mg/m2) have acceptable toxicity and predictable
pharmacokinetics in children [21]. Although 1 patient in
study B showed secondary graft failure, donor-type chime-
rism was achieved again after steroid pulse therapy.
A conditioning regimen in addition to the use of radiation
has also been shown to improve outcomes and enhance
engraftment [5,6]. Nevertheless, many concerns about radi-
ation, including secondary malignancy [22] and endocrine
problems [23], make it difﬁcult to use, especially in children.
However, a European Group for Blood and Marrow Trans-
plantation study has documented that a FLU-based regimen
without TBI could be sufﬁcient for children because of the
relative better outcome of children when compared with
that of adults [7]. Improved outcomes resulting from a FLU-
based conditioning regimen without TBI would protect
many patients from radiation toxicity.
In this study we performed ﬁrst-line UD HSCT for patients
without previous IST (37 of 57 patients, 64.9%) Although IST
has been considered as a ﬁrst-line treatment for patients
without a matched sibling donor [3], recent studies have
shown that the outcomes of HSCT with a UD are comparable
with those with a matched sibling donor [24,25]. Because of
the poor failure-free survival of IST [16], early UD HSCT after
IST failure would be a good option to improve patient
outcomes.
As a stem cell source for SAA patients with HSCT, PB has
been shown to be a negative predictor of survival [25,26].
However, in the present study PB as a stem cell source did
not negatively affect survival. Furthermore, study B, which
showed better outcomes, had more PB donors than study A.
Although this ﬁnding is limited because of the small sample
size, FK-based GVHD prophylaxis [9] and the homogeneity of
immunogenetics in the Asia-Paciﬁc population [24] might
alleviate the negative effects of PB. Many donors prefer PB to
BM, and our data suggest that UD HSCT with PB could be
acceptable in cases when only PB is available.
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characteristics of the 2 study groups were different regarding
previous IST history, stem cell source, GVHD prophylaxis
regimen, and timing of the HSCT. The higher incidence of IST
history in study A might be a negative prognostic factor.
Moreover, recent advances in supportive care, such as early
detection of Epstein-Barr virus infection, could affect the
outcome of study B. Although the multivariate analysis
demonstrated that the conditioning regimen was the only
prognostic factor of survival, a small sample size made it
difﬁcult to compare the 2 different conditioning regimens
accurately. Moreover although it is well known that some
telomere diseases, such as dyskeratosis congenita, exist in
SAA patients, this study could not evaluate the telomero-
pathies. In future studies, distinguishing the telomeropathies
from other SAA patients will be needed for more delicate
assessment [27].
In this study we report the results of 2 phase II, pro-
spective, multicenter clinical trials examining a conditioning
regimen for SAA in children receiving UD HSCT. The com-
parison between study A and study B demonstrated that a
reduced-toxicity FLU, Cy, and ATG conditioning regimen may
be an optimal regimen for reducing TRM and enhancing
engraftment.
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